Cyclophosphamide, Alvocidib (Flavopiridol), and Rituximab, a Novel Feasible Chemoimmunotherapy Regimen for Patients with High-Risk Chronic Lymphocytic Leukemia

Alvocidib has demonstrated efficacy in high-risk chronic lymphocytic leukemia (CLL) patients. In this phase I study, we combined cyclophosphamide, alvocidib and rituximab (CAR) in a schema designed to mitigate tumor lysis syndrome (TLS) seen previously with alvocidib. Nine nucleoside analog-naïve, h...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Stephens, Deborah M., Ruppert, Amy S., Maddocks, Kami, Andritsos, Leslie, Baiocchi, Robert, Jones, Jeffrey, Johnson, Amy J., Smith, Lisa L., Zhao, Yuan, Ling, Yonghua, Li, Junan, Phelps, Mitch A., Grever, Michael R., Byrd, John C., Flynn, Joseph M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3934299/
https://ncbi.nlm.nih.gov/pubmed/23867058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.06.006
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia